Site-specific PEGylation at histidine tags.

@article{Cong2012SitespecificPA,
  title={Site-specific PEGylation at histidine tags.},
  author={Yuehua Cong and Estera Pawlisz and Penny Bryant and Sibu Balan and Emmanuelle Laurine and Rita Tommasi and Ruchi Singh and Sitara Dubey and Karolina Peciak and Matthew Bird and Amrita Sivasankar and Julia Swierkosz and Maurizio Muroni and Sibylle Heidelberger and Monika Farys and Farzad Khayrzad and Jeff L. Edwards and George O. Badescu and Ian Hodgson and Charles T Heise and Satyanarayana Somavarapu and John Liddell and Keith B. Powell and Mire Zloh and Ji-won Choi and Antony Godwin and Steve Brocchini},
  journal={Bioconjugate chemistry},
  year={2012},
  volume={23 2},
  pages={248-63}
}
The efficacy of protein-based medicines can be compromised by their rapid clearance from the blood circulatory system. Achieving optimal pharmacokinetics is a key requirement for the successful development of safe protein-based medicines. Protein PEGylation is a clinically proven strategy to increase the circulation half-life of protein-based medicines. One limitation of PEGylation is that there are few strategies that achieve site-specific conjugation of PEG to the protein. Here, we describe… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 105 references

Adnectins: engineered target-binding protein therapeutics

Protein engineering, design & selection : PEDS • 2011

Impact of product-related factors on immunogenicity of biotherapeutics

S. K. Singh
J. Pharm. Sci • 2011

Similar Papers

Loading similar papers…